AbbVie Stock Will $300: Timing and Risks to Watch
AbbVie’s Q1 2026 results show strong immunology growth even as biosimilar challenges weigh on revenue. Analysts debat...
Bear markets test retirement portfolios. This piece explains how risk parity may influence drawdowns and resilience, plus practical steps for retirees.
28,052 articlesAbbVie’s Q1 2026 results show strong immunology growth even as biosimilar challenges weigh on revenue. Analysts debat...
Healthcare megacaps Pfizer and Johnson & Johnson continue to deliver quarterly dividends that can generate reliable i...
The GRID fund has surged about 23% in 2026, outpacing the traditional utilities ETF XLU as AI-enabled grid modernizat...
Snowflake and MongoDB posted solid Q1 results, stoking debate on which cloud data platform is the mongodb snowflake: ...
Two market behemoths, two roadmaps: Palantir’s enterprise AI software and SanDisk’s hyperscale memory hardware race t...
MediaTek launches its most powerful custom AI accelerator to date, tying a 25% discount to early commitments and sign...
Alphabet is shifting from relying on Broadcom to building its own AI chips, aiming to feed GOOG’s hyperscale cloud wh...
A Utah-based defamation suit accuses Kevin O’Leary and Fox News of tying two local political groups to the CCP amid o...
Bill Gates is downshifting his Seattle-area estate footprint, listing a neighboring home and pruning parcels around X...
Viasat swung to a $25 million quarterly profit helped by a $420 million one-time payment, yet Reddit sentiment stays ...
Onto Innovation is emerging as a leading semiconductor play for 2026, rooted in its metrology and advanced packaging ...
Translucent closed a $27 million Series A to expand its AI-native healthcare finance platform, targeting improved rev...